Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5152W HIGH $71.50
Volume
1.03 M
Value Traded
240.63 K
Short % Float
14.52%
-44.39%Week
-46.78%1 Month
-48.97%3 Month
-79.86%6 Month
-99.83%5 Year
-99.76%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
128.85 M
EPS (TTM)
-18.88
P/E Ratio
-
Ent. Value
127.30 M
Total Shares
1.66 M
Float Shares
1.41 M
Insiders
17.36%
Institutions
11.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
BCAB Catalyst Timeline
Dated clinical, regulatory and corporate events for BioAtla, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for BioAtla, Inc.
288Total events
1Upcoming
59Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 1
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 50
◆Pipeline PrioritizationCorporate
Re-evaluating timing and scope of clinical programs including BA3182 Phase 1 enrollment and Phase 3 start for ozuriftamab vedotin
◆Pipeline PrioritizationCorporate
Board initiates formal process to explore strategic options including sale of assets, licensing, partnerships
▼Restructuring LayoffsCorporate
BioAtla implements reduction in force and cost-containment measures
◆Enrollment UpdateBA3182Trial
BioAtla re-evaluating timing and pacing of additional enrollment in Phase 1 study of BA3182
advanced adenocarcinomasource ↗
◆Trial Initiationozuriftamab vedotinTrial
BioAtla re-evaluating timeline to commence Phase 3 study for ozuriftamab vedotin in 2L+ OPSCC
2L+ oropharyngeal squamous cell carcinoma (OPSCC)source ↗
◆Equity OfferingCorporate
Initial closing of SPV transaction expected to occur by January 30, 2026
◆Trial Initiationozuriftamab vedotinTrial
Phase 3 study initiation expected in early 2026 with strategic partner
HPV+ oropharyngeal squamous cell carcinomasource ↗
▲Partnership / Licenseozuriftamab vedotinCorporate
BioAtla and GATC Health announce SPV transaction to advance Oz-V into Phase 3 registrational trial
2L+ oropharyngeal squamous cell carcinomasource ↗
◆Partnership / LicenseCorporate
Partnership transaction expected to be completed by year end 2025
◆Timing GuidancePresentation
BioAtla expects to complete strategic partnership by year end 2025
▼Equity OfferingCorporate
BioAtla enters into agreements for up to $22.5 million flexible financing
◆Quarterly UpdateCorporate
BioAtla to announce Q3 2025 financial results and provide business highlights
▲FDA Feedback ReceivedFDA Meeting
FDA alignment achieved on Phase 3 registrational Oz-V trial design
HPV+ OPSCCsource ↗
▲Poster PresentationPresentation
Poster presentation at SITC 2025: Median OS of 21.5 months in subtypes of refractory soft tissue sarcomas
treatment-refractory leiomyosarcoma, liposarcoma, undifferentiated pleomorphic sarcomasource ↗
◆Poster Presentationozuriftamab vedotinPresentation
Poster presentation at IPVS Conference on Oz-V in HPV+ OPSCC
HPV+ oropharyngeal squamous cell carcinomasource ↗
◆Poster PresentationBA3182Presentation
Preliminary clinical data from Phase 1 study of BA3182 presented at ESMO 2025
treatment refractory metastatic adenocarcinomasource ↗
▲Milestone PaymentBA3362Corporate
Context Therapeutics triggered $2 million milestone payment for CAB-Nectin4-TCE program
▲Type B MeetingFDA Meeting
FDA Type B (End of Phase 2) meeting outcomes announced
Oropharyngeal Squamous Cell Carcinoma (OPSCC)source ↗
▲End Of Phase 2 Meetingozuriftamab vedotinFDA Meeting
End of Phase 2 (Type B) meeting with FDA in September 2025
HPV+ oropharyngeal squamous cell carcinomasource ↗
▲Oral PresentationBA3182Presentation
Promising data from CAB-EpCAM-TCE (BA3182) presented at ESMO
advanced adenocarcinomasource ↗
◆Quarterly UpdateCorporate
BioAtla to announce Q2 2025 financial results and provide business highlights
◆Oral PresentationBA3182Presentation
Oral presentation of Phase I study of BA3182 at ESMO TAT Asia 2025
treatment refractory metastatic adenocarcinomasource ↗
◆Dose Finding UpdateBA3182Trial
Dose escalation continuing at 1.2 mg weekly subcutaneous flat dosing
treatment refractory metastatic adenocarcinomasource ↗
◆Poster PresentationBA3182Presentation
Preliminary Results from a First-in-Human Phase 1 Study of BA3182 presented at ESMO GI 2025
treatment refractory metastatic adenocarcinomasource ↗
◆Enrollment UpdateBA3182Trial
39 patients dosed as of June 20, 2025 in dose-escalation cohorts
treatment refractory metastatic adenocarcinomasource ↗
▲Poster PresentationPresentation
Poster presentation of Phase 2 data for Oz-V in HPV+ OPSCC at ASCO 2025
HPV-associated oropharyngeal squamous cell carcinomasource ↗
◆Topline ReadoutBA3182Clinical Data
Data readout of Phase 1 study anticipated around mid-2025
advanced adenocarcinomasource ↗
●Oral PresentationBA3182Presentation
Invited speaker presentation at PEGS Conference: BA3182: A Novel EpCAM Targeting, Conditionally Active T cell Engager
◆Oral PresentationPresentation
Corporate update and one-on-one investor meetings at Citizens Life Sciences Conference
◆Quarterly UpdateCorporate
First Quarter 2025 Financial Results and Business Highlights Conference Call
▲First Patient DosedBA3182Trial
First three patients dosed at 300 micrograms in Phase 1 dose-escalation study
advanced adenocarcinomasource ↗
◆Oral Presentationozuriftamab vedotinPresentation
Abstract accepted for ASCO 2025 presentation
SCCHNsource ↗
◆Poster PresentationBA3361Presentation
Poster presentation on BA3361, CAB anti-Nectin4-ADC with novel linker system at AACR 2025
pancreatic cancersource ↗
◆Poster PresentationPresentation
Poster presentation on novel senolytic targets and CAB-based drug conjugates at AACR 2025
solid tumorssource ↗
◆Topline ReadoutBA3182Clinical Data
BA3182 Phase 1 dose escalation data readout
solid tumors (EpCAM-positive adenocarcinomas)source ↗
◆Enrollment CompleteBA3011Trial
BA3011 advancing into potentially registrational trial in 2H 2025
sarcomasource ↗
◆Trial InitiationBA3011Trial
Potentially registrational trial initiation for BA3011 in 2H 2025
sarcomasource ↗
◆Poster Presentationmecbotamab vedotinPresentation
Poster presentation at ELCC 2025: Exploratory Analysis of Overall Survival among NSCLC Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin
Non-Small Cell Lung Cancer (NSCLC) with mutated KRASsource ↗
◆Poster Presentationozuriftamab vedotinPresentation
Poster presentation at Mayo Clinic Multidisciplinary Head and Neck Cancer Symposium 2025: Ozuriftamab Vedotin (BA3021) Phase 2 experience in Heavily Pretreated SCCHN
Squamous Cell Carcinoma of the Head and Necksource ↗
▲Oral Presentationmecbotamab vedotinPresentation
Data presented at European Lung Cancer Congress 2025
NSCLC with mKRAS mutationssource ↗
▲Oral Presentationozuriftamab vedotinPresentation
Updated data presented at Mayo Multidisciplinary Head and Neck Cancer Symposium 2025
treatment-refractory SCCHNsource ↗
Past FDA Catalysts and PDUFA Decisions
How BCAB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | mecbotamab vedotin (CAB-AXL-ADC) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$47M
Pipeline Value
Overvalued
Valuation Signal
4
Drugs Scored
0.4x
rNPV / MCap
BioAtla, Inc. faces pipeline headwinds (32/100), with $824M risk-adjusted pipeline value, led by Ozuriftamab Vedotin in Head and Neck Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ozuriftamab Vedotin ADCCompletedNCT05271604 | Head and Neck Cancer | Phase 2 | COMPLETED | 42 | Sep 22, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every BCAB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Mecbotamab Vedotin | treatment-refractory soft tissue sarcomas | Phase 2 | 2025-11-07 | In a Phase 2 trial, Mecbotamab Vedotin demonstrated a median overall survival of 21.5 months in 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma, compared to approximately 12 months with approved therapies.Read More | BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SHORT JAY M PHDDirector, Officer (Chief Executive Officer) | Acquisition | 430,000 2,659,603 held | $0.00 | 03/11/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BCAB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 945.00 K | 1.37 M |
BCAB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BCAB ranks across every disease it competes in
Competitive Position is a premium feature
See how BCAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBCAB News
About BioAtla, Inc.
Headquarters11085 TORREYANA ROAD, SAN DIEGO, CA, 92121
Founded2007
BIOPHARMAWATCH ELITE PLUS
Trade the next BCAB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime